Jounce shares take a beat­ing as their lead drug spurs on­ly a weak re­sponse in PhII — tri­al halt­ed

A lit­tle over two months af­ter Jounce Ther­a­peu­tics $JNCE sold its lat­est ex­per­i­men­tal can­cer drug to Gilead, the com­pa­ny’s lead pro­gram has failed to clear the Phase II hur­dle.

Jounce’s Phase II study eval­u­at­ing the ICOS-tar­get­ing vo­prate­limab in non-small cell lung can­cer flopped with on­ly 1 of 50 pa­tients show­ing an over­all re­sponse, and the com­pa­ny has de­cid­ed to shut the tri­al down rather than con­tin­ue en­roll­ment, the biotech an­nounced Mon­day. Re­searchers had been study­ing whether or not vo­prate­limab could pro­duce a mean­ing­ful re­sponse in com­bi­na­tion with BMS’ Yer­voy for pa­tients with PD-(L)1 re­sis­tant NSCLC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.